Roche announces US$50 billion US expansion targeting gene therapy and AI research capabilities
F. Hoffmann-La Roche has announced an ambitious US$50 billion investment initiative spanning five years, designed to transform the company’s United States pharmaceutical and diagnostics infrastructure. The comprehensive expansion programme addresses critical manufacturing bottlenecks whilst establishing cutting-edge research capabilities across multiple therapeutic domains, creating over 12,000 new positions in the biomedical technology sector.

